Novartis (NVS) to Release Quarterly Earnings on Tuesday

Novartis (NYSE:NVS) is anticipated to release its earnings data before the market opens on Tuesday, April 22nd. Analysts expect Novartis to post earnings of $2.07 per share and revenue of $12.92 billion for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Novartis (NYSE:NVS) last announced its earnings results on Friday, January 31st. The company reported $1.98 EPS for the quarter, beating analysts’ consensus estimates of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. On average, analysts expect Novartis to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Novartis Trading Up 1.0 %

Novartis stock opened at $110.69 on Monday. The stock has a 50-day moving average price of $109.21 and a 200 day moving average price of $106.22. The company has a current ratio of 1.04, a quick ratio of 0.84 and a debt-to-equity ratio of 0.48. The stock has a market cap of $226.26 billion, a PE ratio of 18.83, a P/E/G ratio of 1.70 and a beta of 0.56. Novartis has a 52 week low of $94.72 and a 52 week high of $120.92.

Novartis Dividend Announcement

The firm also recently disclosed a dividend, which was paid on Wednesday, March 12th. Stockholders of record on Wednesday, March 12th were issued a dividend of $3.8695 per share. The ex-dividend date of this dividend was Wednesday, March 12th. Novartis’s dividend payout ratio (DPR) is 42.69%.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Novartis stock. Brighton Jones LLC lifted its holdings in shares of Novartis AG (NYSE:NVS) by 76.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,153 shares of the company’s stock after buying an additional 2,666 shares during the period. Brighton Jones LLC’s holdings in Novartis were worth $599,000 at the end of the most recent reporting period. 13.12% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

NVS has been the topic of several recent analyst reports. BNP Paribas upgraded shares of Novartis to a “strong-buy” rating in a report on Tuesday, April 15th. UBS Group reiterated a “neutral” rating on shares of Novartis in a research note on Thursday, February 13th. StockNews.com raised shares of Novartis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 8th. Morgan Stanley started coverage on Novartis in a report on Wednesday, February 12th. They set an “underweight” rating on the stock. Finally, Barclays restated an “underweight” rating on shares of Novartis in a research note on Monday, February 3rd. Three analysts have rated the stock with a sell rating, six have assigned a hold rating, one has given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $123.38.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.